BNP Paribas Asset Management
ARIA

BNP Paribas Asset Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

BNP Paribas Asset Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-950,851
Closed -$5.94M – 1091
2015
Q4 		$5.94M Sell
950,851
-217
-0% -$1.42K 0.05% 415
2015
Q3 		$5.55M Sell
951,068
-781,727
-45% -$6.02M 0.05% 445
2015
Q2 		$14.3M Sell
1,732,795
-203,578
-11% -$1.8M 0.12% 250
2015
Q1 		$16M Buy
1,936,373
+153,516
+9% +$1.13M 0.12% 243
2014
Q4 		$12.2M Buy
1,782,857
+239,507
+16% +$1.5M 0.1% 262
2014
Q3 		$8.33M Buy
1,543,350
+922,311
+149% +$5.39M 0.07% 320
2014
Q2 		$3.96M Buy
621,039
+99,122
+19% +$682K 0.03% 513
2014
Q1 		$4.21M Sell
521,917
-39,520
-7% -$308K 0.03% 476
2013
Q4 		$3.83M Buy
561,437
+408,704
+268% +$2.21M 0.03% 461
2013
Q3 		$2.81M Buy
+152,733
New +$2.97M 0.02% 525

Other funds holding ARIA

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

BNP Paribas Asset Management's ARIA Position: Q1 2016 in Review

BNP Paribas Asset Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2016, closing a stake of 950,851 shares — an estimated $5.94M sold.

BNP Paribas Asset Management first reported a position in ARIA in Q3 2013 and held it in 10 quarters. The position peaked at $16M in Q1 2015. 162 funds tracked by Wall St. Rank hold ARIA as of Q1 2016.

  • BNP Paribas Asset Management reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
  • BNP Paribas Asset Management sold 950,851 Ariad Pharmaceuticals Inc shares in Q1 2016, an estimated $5.94M.
  • BNP Paribas Asset Management first reported a position in Ariad Pharmaceuticals Inc in Q3 2013 and held it in 10 quarters.
  • BNP Paribas Asset Management's Ariad Pharmaceuticals Inc position peaked at $16M in Q1 2015.
  • 162 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2016.

Based on BNP Paribas Asset Management's 13F filing for Q1 2016, filed 16 May 2016.